anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants in this group were randomized to the hearing intervention (HI) group at ACHIEVE trial baseline and received a best practices hearing rehabilitation treatment program, consisting of fitting with hearing aids and other hearing assistive technologies along with comprehensive, individualized hearing rehabilitation sessions with a study audiologist spaced over the 2-3 months post-fitting designed to provide all the active components of the intervention. Participants also received semi-annual booster sessions with the study audiologist. These participants will continue to receive hearing healthcare from the study audiologist and complete semi-annual sessions for 3 additional years.
SOLIQUA 100/33

As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to SOLIQUA 100/33 in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

After 30 weeks of treatment with SOLIQUA 100/33 in two phase 3 trials, the incidence of formation of anti-insulin glargine antibodies was 21.0% and 26.2%. In approximately 93% of the patients, anti-insulin glargine antibodies showed cross-reactivity to human insulin. The incidence of formation of anti-lixisenatide antibodies was approximately 43%. 

Lixisenatide

In the pool of 9 placebo-controlled studies, 70% of patients exposed to lixisenatide tested positive for anti-lixisenatide antibodies during the trials. In the subset of patients (2.4%) with the highest antibody concentrations (>100 nmol/L), an attenuated glycemic response was observed. A higher incidence of allergic reactions and injection-site reactions occurred in antibody positive patients [see Warnings and Precautions (5.8)].

Anti-lixisenatide antibody characterization studies have demonstrated the potential for development of antibodies cross-reactive with endogenous GLP-1 and glucagon, but their incidence has not been fully determined and the clinical significance of these antibodies is not currently known.

No information regarding the presence of neutralizing antibodies is currently available.
BACKGROUND: Acute kidney injury (AKI) is a frequent complication of severe acute pancreatitis (SAP). Previous investigations have revealed the involvement of FTO alpha-ketoglutarate-dependent dioxygenase (FTO) and aquaporin 3 (AQP3) in AKI. Therefore, the aim of this study is to explore the association of FTO and AQP3 on proximal tubular epithelial cell damage in SAP-induced AKI.
METHODS: An in-vitro AKI model was established in human proximal tubular epithelial cells (PTECs) HK-2 via tumor necrosis factor-α (TNF-α) induction (20 ng/mL), after which FTO and AQP3 expression was manipulated and quantified by quantitative real-time PCR and Western blotting. The viability and apoptosis of PTECs under various conditions, and reactive oxygen species (ROS), superoxide dismutase (SOD), and malonaldehyde (MDA) levels within these cells were measured using commercial assay kits and flow cytometry. Methylated RNA immunoprecipitation and mRNA stability assays were performed to elucidate the mechanism of FTO-mediated N6-methyladenosine (m6A) modification. Western blotting was performed to quantify β-catenin protein levels in the PTECs.
RESULTS: FTO overexpression attenuated the TNF-α-induced decrease in viability and SOD levels, elevated apoptosis, increased levels of ROS and MDA, and diminished TNF-α-induced AQP3 expression and reduced β-catenin expression, but its silencing led to contradictory results. FTO negatively modulates AQP3 levels in RTECs in an m6A-depednent manner and compromises AQP3 stability. In addition, all FTO overexpression-induced effects in TNF-α-induced PTECs were neutralized following AQP3 upregulation.
CONCLUSION: FTO alleviates TNF-α-induced damage to PTECs in vitro by targeting AQP3 in an m6A-dependent manner.
A system and method for predicting the effect of patient self-care actions on a disease control parameter. A future disease control parameter value X(tj) at time tj is determined from a prior disease control parameter value X(ti) at time ti based on an optimal control parameter value R(tj) at time tj, the difference between the prior disease control parameter value X(ti) and an optimal control parameter value R(ti) at time ti, and a set of differentials between patient self-care parameters having patient self-care values SM(ti) at time ti and optimal self-care parameters having optimal self-care values OM(ti) at time ti. The differentials are multiplied by corresponding scaling factors KM. The system includes an input device for entering the patient self-care values SM(ti). A memory stores the optimal control parameter values R(ti) and R(tj), the prior disease control parameter value X(ti), the optimal self-care values OM(ti), and the scaling factors KM. A processor in communication with the input device and memory calculates the future disease control parameter value X(tj). A display is connected to the processor to display the future disease control parameter value X(tj) to a patient.
Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil, sufentanil. Sevoflurane inhalation will be stopped at the end of surgery.
Standard of care: Prone position applied according to standard indications (severe ARDS not improving with 12-24 hours of mechanical ventilation with PaO2-to-FiO2 ratio (PAF) \< 150 mmHg with FiO2 of ≥0.6, a positive end-expiratory pressure (PEEP) of ≥5 cm of water, and a tidal volume of about 6 ml per kilogram of predicted body weight). Until one of the following are met: Substantial improvement and/or imminent extubation, Worsening oxygenation with prone position, Serious Adverse Reactions (SARs) occurring during a prone session and leading to its immediate interruption.
FIELD: chemistry; biochemistry. ^ SUBSTANCE: invention relates to veterinary parasitology. The strain is deposited in the collection of the All-Russian Research Veterinary Institute of Poultry Science under registration number KE No.2. The strain is used to produce vaccines, diagnostic preparations and conducting scientific research. ^ EFFECT: strain is specific for chicken only, has good immunogenic properties, is sensitive to coccidiostats. ^ 2 tbl, 2 ex
The invention relates to glycyrrhizic acid self-emulsifying preparation concentrated solution using a phospholipid complex as an intermediate and a preparation method thereof. The invention aims to enable the provided concentrated solution to have the characteristics of high lipid solubility and high bioavailability. The method has the characteristics of simplicity for preparation and low cost. The invention adopts the technical scheme that the concentrated solution for a glycyrrhizic acid self-emulsifying preparation sequentially comprises the glycyrrhizic acid phospholipid complex, an emulsifier, a co-emulsifier and an oil phase or aliphatic ester according to the weight ratio of (1 to 2):(1 to 8):(2 to 5):(2 to 9). The preparation method of the concentrated solution for the glycyrrhizic acid self-emulsifying preparation is carried out according to the following steps: weighing the phospholipid complex; sequentially adding the emulsifier, the co-emulsifier and the oil phase or aliphatic ester; and stirring and dissolving to obtain the concentrated solution. A preparation method of the glycyrrhizic acid phospholipid complex is carried out according to the following steps of: taking phospholipid and glycyrrhizic acid; performing the dissolution reaction in an organic solvent; stirring to a clear state; and drying or adding an inert solvent to carry out precipitation separation to remove the organic solvent so as to obtain an anhydrous substance of the glycyrrhizic acid phospholipid complex.
Galcanezumab given by subcutaneous (SC) injection at 120mg dose once a month for 6 months. Participants received a loading dose of 240mg (2 injections of 120mg each) was administered at visit 3 only.
Numerous studies have confirmed the relationship between individual risk and time preference and obesity. Nevertheless, none has studied the effect of these attitudes on chronic (long-term) obesity. This study used Indonesia Family Life Survey (IFLS) data from 16,366 individuals. It tracked their obesity status in 2007 and 2014 by calculating body mass index, the ratio between body weight and square of height. Besides the conventional risk-averse and risk-tolerant behaviour, the IFLS sample includes people who fear uncertainty related to the status quo bias. The ordered logit regression results show that past impatience, risk tolerance, and status quo bias behaviour (in 2007) are associated with transient or chronic obesity, while only current behaviour of status quo bias (in 2014) is associated with obesity. Furthermore, our study confirms that chronic obesity in Indonesia is prevalent among highly educated, high-income, and urban-centric individuals, exacerbated by impatience, risk tolerance, and uncertainty aversion. Thus, providing information on the risk of obesity and food calories, giving the incentive to avoid obesity, and improving the quality of built environments such as public parks, public transportation, and footpath could help prevent the rising obesity prevalence.
ABSTRACT The object of the present invention is to provide a tablet that dissolves rapidly in the oral cavity (fast soluble tablets) that can be produced by a simple method without special preparation technology. The present invention is a fast soluble tablet which comprises two features: ? the tablet base component is a sugar alcohol or the like, and ? a kneaded mixture of a drug and a sugar alcohol or the like is subjected to compressive shaping prior to drying in the process when compressive shaped for pre-paring tablets by wet granulation. The fast soluble tablet of the present invention can be produced by a modification of the conventional tableting method, and possesses sufficient physico-chemical stability. - 2 3 -
This study examined the efficacy of computed tomography (CT)-based Hounsfield units (HU) as early predictors of aseptic bone necrosis, a serious post-cranioplasty complication after autologous cranioplasty. In total, 100 patients who underwent decompressive craniectomy and subsequent autologous cranioplasty were included. The radiodensity of the bone flap was evaluated in HU from CT scans at five follow-up timepoints. HU thresholds were established to predict the development of aseptic bone necrosis. HU demonstrated a declining trend throughout the follow-up period in all patients. Necrosis type I patients showed significant differences at all timepoints from 3 months post-procedure onwards, while necrosis type II patients displayed a significant decline in HU at every follow-up. Optimal thresholds with cut-off A (91.23% of initial HU) and cut-off B (78.73% of initial HU) were established to predict the occurrence of bone necrosis and the need for artificial bone replacement, respectively. Our findings demonstrated the utility of CT-based HU measurements as a simple, non-invasive tool for the early prediction of aseptic bone necrosis following autologous cranioplasty. By delineating specific HU thresholds, our study offers a valuable guide for orchestrating timely follow-ups and advising patients on the necessity of proactive interventions.
Sarilumab 100 mg qw, 150 mg qw or 100 mg q2w SC injections as in Part A on top of MTX up to dose selection. After dose selection, participants were not continued but were allowed to participate in the open-label, long-term, extension study SARIL-RA-EXTEND (LTS11210).
In 1939, Hamman´s syndrome, also know as spontaneous pneumomediastinum, was characterized by the presence of pneumothorax, subcutaneous emphysema, and pneumorrhachis. It is believed to arise from barotrauma during vaginal labor, causing alveolar membrane rupture and subsequent air leakage. Clinical manifestations are often nonspecific. Management strategies vary based on symptom severity and complications, high-concentrations oxygen therapy promoting air absorption. We present the case of an 18-year-old male patient with a history of bronchial asthma and tobacco use, underscoring the need for heightened awareness of Hamman´s syndrome in similar cases. Prompt diagnosis and appropriate management are crucial to prevent or quickly address potential life-threatening complications. Diagnosing this syndrome in male patients can be particularly challenging, as it was initially associated with complications from vaginal labor, potentially leading to poorer outcomes.
50 patients with suspected or confirmed OPC will undergo a transcervical ultrasound during their first visit at the Vanderbilt Head and Neck Clinic in addition to other imaging modalities (CT, MRI and/or PET) as indicated as part of routine clinical care; patients will also be asked to provide a blood specimen. Ultrasound exams will be performed by a clinician blinded to details of the case. All patients will have a CT as part of their diagnostic work-up. Sensitivity of ultrasound to detect tumors identified by CT will be determined. Approximately 40% of patients are expected to test negative on CT requiring MRI and/or PET imaging. Among this subset, the sensitivity of ultrasound to detect tumors identified by either PET and/or MRI will be determined. Tumor size will be determined by 3 ultrasound measurements along the largest diameter of the tumor; agreement between ultrasound and the clinical imaging modalities will be calculated. The investigators will recruit an additional 78 OPC patients with pre-treatment serum banked within the Vanderbilt Head and Neck Cancer Biorepository (18 HPV-negative, 60 HPV-OPC) for HPV serologic analyses; total: 128 samples. Sensitivity and specificity of HPV16 E6 antibodies for detecting HPV-OPC will be calculated. As an exploratory aim, the proportion of tumors undetectable by CT, PET, and MRI, but detected by ultrasound will be determined.
Acute glaucoma following carotid artery recanalization is a rare but severe complication of underlying ocular ischemic syndrome. We present a case of a 71-year-old woman with ocular ischemic syndrome and severe stenosis of the right internal and external carotid artery undergoing carotid artery stenting. Immediate postprocedural angiography showed pronounced reperfusion of the ophthalmic artery. Subsequently, the patient developed vision-threatening acute glaucoma despite treatment with acetazolamide. Monitoring of intraocular pressure is important in patients who are at risk of developing ocular ischemic syndrome because of internal carotid artery stenosis. Interventionalists should also assess the degree of vascular collateralization from the external carotid artery.
<P>PROBLEM TO BE SOLVED: To provide isolated protein complexes including a growth factor, e.g. insulin-like growth factor (IGF)-I, IGF-II, vascular endothelium growth factor (VEGF) or platelet-derived growth factor (PDGF), or at least domains of the growth factor that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of vitronectin or fibronectin.  <P>SOLUTION: The protein complexes may be in the form of oligo-protein complexes or single, synthetic proteins where the growth factor and vitronectin or fibronectin sequences are joined by a linker sequence, in the case of a single synthetic protein. In particular forms, vitronectin or fibronectin sequences do not include at least any of a heparin-binding domain and a polyanionic domain. There are provided uses of these protein complexes for stimulating or inducing at least any of cell migration and/or proliferation which may have use in wound healing, tissue engineering, cosmetic and therapeutic treatments, e.g. skin replacement and skin replenishment and treatment of burns where epithelial cell migration is required. In other embodiments, there is provided inhibition of cancer cell metastasis, particularly in relation to breast cancer.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Process for recovering the active principle (A) of the vaccine or serum against Pseudomonas aeniginosa comprises (i) culturing, pref. in the absence of impurities in the culture medium, a vinilent strain of the bacterium of morphological type 1a; (ii) collecting the cells, removing any culture medium impurities if necessary; (iii) washing with a liq. of low ionic strength, such as distilled water, to remove the labile bacterial excretion products; (iv) suspending the washed cells in a liq. and heating the suspension to 37-80 degrees C at which temp. the medium has sufficient ionic strength to extract the components (peribaccilary substances) from the capsule surrounding the bacterium, then (v) removing solids and collecting the soln. of (A). Vaccines contg. (A) and antisera obtained from animals inoculated with (A) are also new. (A) are at least as active as previously prepared antigen extracts but since the bacterial excretion products, esp. extracellular enzymes, have been removed they are much less toxic. The vaccines/antisera can be used for prophylaxis/treatment of humans and animals.
Each participant will lie in a supine position. The treating investigator (TI) will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The TI will side bend the participant's spine towards the non-painful side, reach through the participant's hands and perform a spinal rotation away from the painful side. The TIs other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side. Lastly, the TI will take up the slack and maintain the pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If the participant can tolerate the pressure for at least 5 seconds. Then, the subjects will be re-positioned to the starting position.
ETHNOPHARMACOLOGICAL RELEVANCE: Hancornia speciosa Gomes is a fruit and medicinal species used for treating infectious diseases of the genitourinary system. However, its mechanism of action against microbes is still not fully understood. Infections in the genitourinary system caused by Candida spp. are associated with its fungal resistance and pathogenicity. New plant-derived compounds are an alternative to fight these Candida infections.
AIM OF THE STUDY: The objective of this study was to evaluate the anti-Candida effects of extracts of the stem bark of H. speciosa. This research investigated the chemical composition of sulfuric ether (EEHS) and methanolic (MEHS) extracts, their drug-modifying action on fluconazole, and their anti-virulence action on the morphological transition of Candida species.
MATERIALS AND METHODS: The extracts (EEHS and MEHS) of the stem bark of H. speciosa were chemically characterized via qualitative phytochemical screening and by liquid chromatography coupled with mass spectrometry (UPLC-MS-ESI-QTOF). The extracts were evaluated regarding their antifungal effects and fluconazole-modifying activity against Candida albicans, Candida krusei, and Candida tropicalis using the broth microdilution method. Additionally, the study evaluated the inhibition of fungal virulence in Candida species through morphological transition assays.
RESULTS: The phytochemical screening revealed the presence of anthocyanidins, anthocyanins, aurones, catechins, chalcones, flavones, flavonols, flavanones, leucoanthocyanidins, tannins (condensed and pyrogallic), and xanthones in both extracts of the stem bark of H. speciosa. The UPLC-MS-ESI-QTOF analysis identified the same compounds in both extracts, predominating phenolic compounds. Some compounds were first time recorded in this species: gluconic acid, cinchonain IIb, cinchonain Ib isomer, and lariciresinol hexoside isomers. Most of the intrinsic antifungal activity was observed for the MEHS against C. krusei (IC50: 58.41 μg/mL). At subinhibitory concentrations (MC/8), the EEHS enhanced the action of fluconazole against all Candida strains. The MEHS exhibited greater efficacy than fluconazole inhibiting C. krusei growth. The EEHS completely inhibited hyphae appearance and reduced pseudohyphae formation in C. albicans.
CONCLUSION: The stem bark of H. speciosa is a rich source of bioactive compounds, especially phenolic. Phenolic compounds can have important roles in fighting infectious diseases of the genitourinary system, such as candidiasis. The extracts of H. speciosa improved the action of the drug fluconazole against Candida species, inhibited hyphae appearance, and reduced pseudohyphae formation. The results of this study can support the development of new therapeutics against resistant strains of Candida.
At onset of signs/symptoms, subjects will apply assigned patch, and return to study center within 24 hours. Patch will be worn continuously, being replaced as needed.
Patients undergo enhancement MRI examination every 3 months in first two years, and then performed every 6 months until the brain metastasis occur. Once brain metastases occur, brain radiotherapy and systemic treatment should be conducted with the follow-up observation of brain enhancement MRI continuing.
Use of xylitol for the gustatory masking of chemotherapeutic agents of the quinolone-o-naphthyridonecarboxylic acid group, especially enrofloxacin, administered in foods for pigs, including water. The xylitol may be alone, or together with other synergists, especially arginine. The xylitol is in a proportion, by weight, comprised between 1 to 100 parts of xylitol per 1 part of quinolone, and more especially between 20 to 70 parts of xylitol per 1 part of chemotherapeutic. Arginine, if present, is in a proportion by weight, comprised between 0.5 to 2 parts of arginine per 1 part of chemotherapy. The use of xylitol also comprises the combination of other xylitol synergists or their derivatives, other than arginine, for increasing the masking effect of xylitol. (Machine-translation by Google Translate, not legally binding)
The present invention provides a method of treating cancer in a patient (e.g., a human patient) in need thereof, the method comprising administering a therapeutically effective regimen, the regimen comprising administering to a patient in need thereof a compound that targets 67 laminin receptor (67LR). In a particular embodiment, the compound that targets 67LR is an antibody or antibody fragment. In particular, the present invention provides a method of treating cancer comprising administering to a patient in need thereof an antibody that binds to 67LR. The present invention also provides a method of treating cancer comprising administering to a patient in need thereof an antibody conjugate, wherein the antibody conjugate comprises an antibody that binds to 67LR linked to a therapeutic agent, a protein toxin, a cytotoxic agent or other moiety. The present invention provides pharmaceutical compositions for the treatment of cancer comprising an antibody that binds to 67LR in an amount effective to reduce cancer stem cells and/or cancer cells in a patient. The invention also provides for means to detect and monitor cancer stem cells based on their expression of 67LR.